Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanogen to Focus on High Growth Clinical Diagnostics Markets with Real Time and Point of Care Products; Undertakes Evaluation of Strategic Alternative

Abstract:
Nanogen, Inc. (Nasdaq:NGEN) today announced that it is evaluating strategic alternatives for its microarray business as part of an aggressive plan to achieve profitability. The microarray business includes the company's NanoChip instrument system and related multiplexed reagents and consumables. The company has retained Credit Suisse to assist in the evaluation of alternatives which may include a sale, partnering or closure of the array business. The company expects to complete its evaluation of strategic alternatives within sixty to ninety days.

Nanogen to Focus on High Growth Clinical Diagnostics Markets with Real Time and Point of Care Products; Undertakes Evaluation of Strategic Alternative

SAN DIEGO, CA | Posted on September 17th, 2007

The goal of the strategic evaluation is to create a restructured business at Nanogen that can reach profitability faster and with greater predictability. The restructured business will continue to focus on clinical diagnostic markets with emphasis on real-time molecular and rapid point of care products. Nanogen has a strong intellectual property and technology base in both of these areas and Nanogen's products are widely adopted and well accepted by customers.

"Financial expectations for the restructured business have not been completed and are dependent on the outcome of the strategic evaluation," said Robert Saltmarsh, Nanogen's CFO. "While specific goals will be discussed after the conclusion of our evaluation process, we expect that sale or closure of the microarray business will decrease expenses and improve cash flow by at least fifteen million dollars ($15 million) annually. We also expect the restructured business will show revenue growth on a year over year basis."

"In taking this course of action, we recognize that our microarray technology is very good and customer reception is positive. However, multiplex molecular testing remains an early stage market with slower growth and lower testing volumes than we expected," said Howard Birndorf, Nanogen's chairman and CEO. "The cost and effort to develop the broad product menu needed to be successful while also working to develop the clinical market over the next several years are large efforts and are expenses that Nanogen can no longer afford on its own."

"In the past year, we have begun to build a solid business with our real-time PCR products and Point of Care rapid testing solutions. By focusing on these businesses, we expect to significantly grow our presence in the diagnostics market and improve our business performance," said David Ludvigson, Nanogen's president and COO. "We hold significant intellectual property in the molecular and point of care areas and intend to continue developing proprietary, technology based products that add value in the clinical diagnostic market and are well accepted by customers."

Webcast of Conference Call

Interested investors and others may participate in the conference call by dialing 866-578-5784 for US/Canada participants and 617-213-8056 for international participants. The participant code will be 64018228.

Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at http://www.nanogen.com , and will be archived for one year. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on September 18, and can be accessed via telephone at 888-286-8010 for US/Canada participants and 617-801-6888 for international participants. The passcode 36006805 will be required to listen to the playback.

####

About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip®400 electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information, please join company executives in a conference call that will be held at 9:00 AM EDT on September 18, 2007.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These risks and uncertainties include the outcome of the evaluation of the strategic alternatives as well as the risks and uncertainties discussed under the caption "Risk Factors" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements. The Company advises that there can be no assurance that this process will result in any specific transaction. The Company will not publicly disclose further information regarding the status of its evaluation until the process has been completed or unless or until the Company deems it necessary or appropriate.

For more information, please click here

Contacts:
Nanogen, Inc.
Chief Financial Officer
Robert Saltmarsh, 858-410-4600

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanotech Grants Options September 22nd, 2016

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Carbodeon Ltd Oy Closes EUR 1.5 million Funding Round From Straightforward Capital: Carbodeon will accelerate its nanodiamonds business and expand manufacturing capacity August 21st, 2016

Nanomedicine

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Announcements

Leti and Taiwanese Tech Organizations Sponsoring Workshop in Taipei on MEMS, IoT, Smart Lighting Applications, System Reliability & Security September 28th, 2016

Oxford Instruments systems now facilitate water purification technology September 27th, 2016

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Tools

Oxford Instruments systems now facilitate water purification technology September 27th, 2016

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Oxford Instruments is ‘Bringing the Nanoworld Together’ in India once again - 22 - 23 November 2016 | IISc Bangalore September 21st, 2016

Bruker Introduces Complete Commercial AFM-Based SECM Solution: PeakForce SECM Mode Enables Previously Unobtainable Electrochemical Information September 20th, 2016

Events/Classes

Leti and Taiwanese Tech Organizations Sponsoring Workshop in Taipei on MEMS, IoT, Smart Lighting Applications, System Reliability & Security September 28th, 2016

Oxford Instruments is ‘Bringing the Nanoworld Together’ in India once again - 22 - 23 November 2016 | IISc Bangalore September 21st, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic